Last reviewed · How we verify
AZD 2115, Dose 2
At a glance
| Generic name | AZD 2115, Dose 2 |
|---|---|
| Sponsor | Pearl Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |